Display options
Cite
Wüthrich B, Gerber M. Levocabastine eye drops are effective and well tolerated for the treatment of allergic conjunctivitis in children. Mediators Inflamm. 1995;4(7):S16-20doi: 10.1155/S0962935195000792.
Wüthrich, B., & Gerber, M. (1995). Levocabastine eye drops are effective and well tolerated for the treatment of allergic conjunctivitis in children. Mediators of inflammation, 4(7), S16-20. https://doi.org/10.1155/S0962935195000792
Wüthrich, B, and Gerber, M. "Levocabastine eye drops are effective and well tolerated for the treatment of allergic conjunctivitis in children." Mediators of inflammation vol. 4,7 (1995): S16-20. doi: https://doi.org/10.1155/S0962935195000792
Wüthrich B, Gerber M. Levocabastine eye drops are effective and well tolerated for the treatment of allergic conjunctivitis in children. Mediators Inflamm. 1995;4(7):S16-20. doi: 10.1155/S0962935195000792. PMID: 18475684; PMCID: PMC2365677.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1995;4(7):S16-20. doi: 10.1155/S0962935195000792.

Levocabastine eye drops are effective and well tolerated for the treatment of allergic conjunctivitis in children.

Mediators of inflammation

B Wüthrich, M Gerber

Affiliations

  1. Allergy Unit Department of Dermatology University Hospital Zürich Switzerland.

PMID: 18475684 PMCID: PMC2365677 DOI: 10.1155/S0962935195000792

Abstract

This open-label, prospective, multicentre, 4-week trial was undertaken to assess the efficacy and tolerability of twice daily levocabastine eye drops (0.5 mg/ml), with sodium cromoglycate nasal spray for the relief of concurrent nasal symptoms if required, in a total of 233 children with seasonal allergic conjunctivitis. No correlation between efficacy, tolerability and age was found. Investigator assessments revealed that the total severity of ocular symptoms decreased by 84 +/- 34% in patients < 12 years and 85 +/- 30% in those >/= 12 years, with corresponding reductions in the total severity of ocular findings of 84% in both patient groups over the 4-week treatment period. Global assessments of therapeutic efficacy revealed the effect of therapy on ocular symptoms to be excellent or good in 81% of patients < 12 years and 82% of those >/= 12 years after 2 weeks of treatment, with corresponding values at the end of the trial of 88% and 82% in the two groups, respectively. Treatment tolerability was considered to be excellent or good by 94% of patients overall. Application site reactions were the most common adverse event associated with ocular levocabastine, occurring in 13% of patients < 12 years and 9% of those >/= 12 years. Twice daily levocabastine eye drops therefore appear to be effective and well tolerated for the treatment of seasonal allergic conjunctivitis in children.

References

  1. Eur J Ophthalmol. 1994 Apr-Jun;4(2):91-101 - PubMed
  2. Clin Exp Allergy. 1991 Nov;21(6):689-94 - PubMed
  3. Clin Exp Allergy. 1993 Sep;23(9):791-4 - PubMed
  4. Allergy. 1987 Oct;42(7):512-5 - PubMed
  5. Pediatr Allergy Immunol. 1994 Nov;5(4):209-13 - PubMed
  6. Ann Allergy. 1994 May;72(5):429-34 - PubMed
  7. Drugs. 1991 Feb;41(2):202-24 - PubMed
  8. Allergy. 1989 Aug;44(6):432-6 - PubMed
  9. Allergy. 1993 Oct;48(7):519-24 - PubMed
  10. Allergy. 1994 Sep;49(8):611-5 - PubMed

Publication Types